Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02030275 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults

A Phase 2 study of Hypertrophic Scar, sponsored by RXi Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target
5
Study locations

NCT02030275 is a Phase 2 study of Hypertrophic Scar that has completed, run by RXi Pharmaceuticals. The registered enrollment target is 25 participants, below the 41-participant average among 7 other Hypertrophic Scar trials with a reported enrollment target (39% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02030275, a Phase 2 study of Hypertrophic Scar, has completed, sponsored by RXi Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic abdominal scar.

Conditions Studied

Hypertrophic Scar

Interventions

  • DRUG Placebo
  • DRUG RXI-109

Study Locations (5)

Florida

  • - Lake Worth

Illinois

  • - Chicago

Missouri

  • - St Louis

North Carolina

  • - Huntersville

Other

  • - San Pedro Sula

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2013-11
Est. Completion 2016-06
Phase Phase 2

Sponsor

RXi Pharmaceuticals

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02030275

The ClinicalTrials.gov registry entry for NCT02030275 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 41-participant average among 7 other Hypertrophic Scar trials with a reported enrollment target (39% lower). The listed sponsor is RXi Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertrophic Scar appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02030275 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, Illinois, Missouri.

Frequently Asked Questions

What is clinical trial NCT02030275 about?

NCT02030275 is a clinical study titled "A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults". The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic abdominal scar.

What is the current status of trial NCT02030275?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2013-11. Estimated completion is 2016-06.

What conditions does trial NCT02030275 study?

This clinical trial studies the following conditions: Hypertrophic Scar.

What interventions are being tested in trial NCT02030275?

The interventions under investigation include: Placebo (DRUG), RXI-109 (DRUG).

Who is sponsoring clinical trial NCT02030275?

This trial is sponsored by RXi Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02030275 being conducted?

This trial has 5 study locations across Florida, Illinois, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertrophic Scar

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertrophic Scar

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.